Audentes Therapeutics (BOLD) BidaskScore is upgraded to Strongly Bought

Audentes Therapeutics

The BidaskScore of Audentes Therapeutics BOLDBOLD shows that the shares of the company are now BOLDStrongly Bought Strongly Bought by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Sold since May 6.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Audentes Therapeuticsˌ Inc. is a biotechnology companyˌ which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathyˌ AT002 for the treatment of Pompe diseaseˌ and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13ˌ 2012 and is headquartered in San Franciscoˌ CA.

Audentes Therapeutics

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.